
REFERENCES

1. **Adetunji OR, Mani HA, Olujohungbe A, Abraham KAA and Gill GV (2009).** ‘Microalbuminuric anaemia’-the relationship between haemoglobin levels and albuminuria in diabetes. *Diabetes Research and Clinical Practice*; 85(2):179-182 .
2. • **Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, and Holman RR (2000).** Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ*; 321(7258):412-419.
3. **American Diabetes Association (2011).** Diagnosis and Classification of Diabetes Mellitus. *Diabetes care*; 33:62-69.
4. **Arafa NA and Amin GE (2010).**The Epidemiology of Diabetes Mellitus in Egypt: Results of a National Survey. *The Egyptian Journal of Community Medicine*; 28(3):29-43.
5. **Beg M, Khan AR, Katyal P, Siddiqui MA, and Ahmad J (2008).** Erythropoietin response to anaemia in type 2 diabetic nephropathy with varying degrees of renal dysfunction. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2008; 2(4):266-272
6. **Bloomgarden ZT (2004).** Type 2 diabetes in the young: the evolving epidemic. *Diabetes Care*; 27:998-1010.
7. nephropathy with varying degrees of renal dysfunction. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2008; 2(4):266-272
8. **Bloomgarden ZT (2004).** Type 2 diabetes in the young: the evolving epidemic. *Diabetes Care*; 27:998-1010.

-
9. **Bonakdaran S, Gharebaghi M, and Vahedian M (2011).**
Prevalence of anemia in type 2 diabetes and role of renal involvement
Year 2011; 22(2):286-290.
10. **Bosman DR, Winker AS, Marsden JT, MacDougall IC, and Watkins PJ (2001).** Anaemia with Erythropoietin Deficiency occurs early in Diabetic Nephropathy. *Diabetes Care*; 24:495-499.
11. **Brosius FC (2008).** 3rd New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. *Rev Endocr Metab Disord*; 9:245-254.
12. **Caramori ML, Fioretto P, and Mauer M (2003).** Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients is associated with more advanced diabetic lesions. *Diabetes*; 52:1036-1040 .
13. **Caramori ML, Gross JL, Pecis M, and de Azevedo MJ (1999).** Glomerular filtration rate, urinary albumin excretion rate, and blood pressure changes in normoalbuminuric normotensive type 1 diabetic patients: an 8-year follow-up study. *Diabetes Care*; 22:1512-1516.
14. **Cardenas C, Bordiu E, Bagazgoitia J, and Calle-Pascual AL (2004).** Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study. *Diabetes Care*; 27:1454-1457.
15. **Ceelen W, Boterberg T, Smeets P, Van Damme N, Demetter P, Zwaenepoel O, Cesteley L, Houtmeyers P, Peeters M, and Pattyn P (2007).** Recombinant human erythropoietin alpha modulates the effects of radiotherapy on colorectal cancer microvessels. *Br J Cancer*; 96(5):692-700 .
16. **Chagnac A, Weinstein T, Herman M, Hirsh J, Gafer U, and Ori Y (2003).** The effects of weight loss on renal function in patients with severe obesity. *J Am Soc Nephrol*; 14:1480-1486.

-
17. **Chawla T, Sharma D, and Singh A (2010).** Role of the renin angiotensin system in diabetic nephropathy. *World J Diabetes*; 1(5): 141–145.
 18. **Chong ZZ and Maiese K (2007).** Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. *Br J Pharmacol*; 150(7):839-850.
 19. **Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, and Corwin MJ (2007).** Efficacy and safety of epoetin alfa in critically ill patients. *N Engl J Med*; 357(10):965-976 .
 20. **Craig JK, Williams DJ, Riley GS, Smith H, Owens RD, Worthing D, Cavill I, and Phillips OA (2005).** Anemia and Diabetes in the Absence of Nephropathy. *Diabetes Care*; 28(5):1118-1123.
 21. **Dabla PK (2010).** Renal function in diabetic nephropathy. *World J Diabetes*; 1(2): 48–56.
 22. **Deray G, Heurtier A, Grimaldi A, Vacher VL, and Bagnis IC (2004).** Anemia and Diabetes. *Am J Nephrol*; 24:522-526.
 23. **Diabetes UK (2009).** Diabetes in the UK 2009: Key statistics on diabetes
 24. **Dikow R, Schwenger V, Schömig M, and Ritz E (2002).** How should we manage anaemia in patients with diabetes? *Nephrol Dial Transplant*; 17:67-72.
 25. **Dronavalli S, Duka I, and Bakris GL (2008).** The pathogenesis of diabetic nephropathy. *Nat Clin Pract Endocrinol Metab*; 4:444-452.
 26. **El-Minshawy O and El-Bassuoni E (2010).** Anemia and Kidney Dysfunction in Type 2 Diabetic Patients. *Int J Nephrol Urol*; 2(4): 543-552.
 27. **Ezenwaka CE, Jones-LeCointe A, Nwagbara E, Seales D, and Okali F (2008).** Anemia and kidney dysfunction in Caribbean Type 2 diabetic patients. *Cardiovasc Diabeto*; 7:25.

-
28. • **Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, Beckles GL, Saaddine J, Gregg EW, Williamson DF, and Narayan KM (2000).** Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. *J Pediatr*; 136(5):664-672.
29. **Ferrario M, Massa M, Rosti V, Campanelli R, Ferlini M, Marinoni B, De Ferrari GM, Meli V, De Amici M, Repetto A, Verri A, Bramucci E, and Tavazzi L (2007).** Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. *Eur Heart J*; 28(15):1805-1813 .
30. **Fioretto P, Caramori ML, and Mauer M (2007).** The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture. *Diabetologia*; 51:1347-1355.
31. **Fisher JW (2003).** Erythropoietin: physiology and pharmacology update. *Exp Biol Med (Maywood)*; 228(1):1-14.
32. **Fisher JW (2010).** Landmark advances in the development of erythropoietin. *Experimental Biology and Medicine*, 235 (12):1398-1411.
33. **Flores JC, Hirschhorn J, and Altshuler D (2003).** The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. *Annu Rev Genomics Hum Genet*; 4:257-291.
34. **Fu Q and Van Eyk JE (2006).** Proteomics and heart disease: identifying biomarkers of clinical utility. *Expert Rev Proteomics*; 3(2):237-249 .
35. **Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, and Koch WJ (2007).** Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. *Am J Physiol Heart Circ Physiol*; 293(1):H60-68.
36. **Gloyn AL (2003).** The search for type 2 diabetes genes. *Ageing Res Rev*; 2:111-127.

-
37. **Graham UM, Magee GM, Hunter SJ, and Atkinson AB (2010).**
38. Diabetic nephropathy and chronic kidney disease at a busy diabetes clinic: A study of Outpatient Care and suggestions for improved care pathways at a subspecialty specialist diabetic renal clinic. *Ulster Med J*; 79 (2):57-61.
39. • **Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, and Zelmanovitz T (2005).** Diabetic nephropathy: diagnosis, prevention, and treatment. *Diabetes Care*; 28:164-176.
40. **Hansen L (2003).** Candidate genes and late-onset type 2 diabetes mellitus. Susceptibility genes or common polymorphisms? *Dan Med Bull*; 50:320-346.
41. • **Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, and Blackwell KL (2006).**
42. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. *Mol Cancer Ther*; 5(2):356-361.
43. **Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, and Pajonk F (2006).** Do erythropoietin receptors on cancer cells explain unexpected clinical findings? *J Clin Oncol*; 24(29):4708-4713.
44. **Henry DH, Bowers P, Romano MT, and Provenzano P (2004).** Epoetin alfa. Clinical evolution of a pleiotropic cytokine. *Arch Intern Med*; 164(3):262-276.
45. **Hu FB (2003).** Sedentary lifestyle and risk of obesity and type 2 diabetes. *Lipids*; 38:103-108.
46. **Jelkmann W (2011).** Regulation of erythropoietin production. *The Journal of Physiology*; 589 (6):1251–1258.
47. **Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL; and DCCT/EDIC Research Group (2003).** Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. *Kidney Int*; 64(3):817-828.

-
48. **Joss N, Patel R, Paterson K, Simpson K, Perry C, and Stirling C (2007).** Anaemia is common and predicts mortality in diabetic nephropathy. *QJM: An International Journal of Medicine*; 100:641-647.
49. **Kaku K (2010).** Pathophysiology of Type 2 Diabetes and Its Treatment Policy. *JMAJ*; 5:41-46.
50. **Kanbay M, Akcay A, Delibasi T, Uz B, Kaya A, Koca C, Turgut F, Bavbek N, Uz E, Duranay M, and Yigitoglu R (2007).** Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. *Adv Ther*; 24(2):346-352.
51. • **Kim KM, Baeka HK, Lima JD, Kimb KY, Kanga IM, Leea WK, and Songa HK (2009).** Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. *Journal of Diabetes and Its Complications*; 24(2): 90-95.
52. **Krolewski AS, Ng DP, Canani LH, and Warram JH (2001).** Genetics of diabetic nephropathy: how far are we from finding susceptibility genes? *Adv Nephrol Necker Hosp*; 31:295-315 .
53. **Lai SY and Grandis JR (2006).** Understanding the presence and function of erythropoietin receptors on cancer cells. *J Clin Oncol*; 24(29):4675-4676 .
54. **Levin A, Thompson CR, Ethier J, et al.** Left Ventricular Mass Index Increase in Early Renal Disease: Impact of Decline in Hemoglobin. *Am J Kidney Dis*. 1999;34:125-34
55. **Lean ME (2000).** Obesity: burdens of illness and strategies for prevention or management. *Drugs Today (Barc)*; 36:773-784.
56. **Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, and Vercammen E (2005).** Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. *J Clin Oncol*; 23(25):5960-5972 .

-
- 57.**Li Y, Lu Z, Keogh CL, Yu SP, and Wei L (2007).** Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. *J Cereb Blood Flow Metab*; 27(5):1043-1054.
- 58.**Maiese K, Chong ZZ, Shang YC (2008).** Raves and risks for erythropoietin. *Cytokine Growth Factor Rev*; 19 (2):145-55.
- 59.**Maiese K, Li F, and Chong ZZ (2004).** Erythropoietin in the brain: can the promise to protect be fulfilled. *Trends Pharmacol Sci*; 25 (11):577-583.
- 60.**Maiese K, Li F, and Chong ZZ (2005).** New avenues of exploration for erythropoietin. *JAMA*; 293(1):90-95 .
- 61.**McCulley WD (2005).** Death to diabetes the six stages of type 2 diabetes. *Current Diabetes Reviews*; 1:1-109.
- 62.**Mocks J.** Cardiovascular Mortality in Haemodialysis Patients Treated with Epoetin Beta – A Retrospective Study. *Nephron* 2000;86:455-62
- 63.**McGill JB and Bell DS (2006).**Anemia and the role of erythropoietin in diabetes. *Journal of Diabetes and Its Complications*; 20(4): 262 272.
64. • **Meguro S, Tomita M, Katsuki T, KatoK , Oh H, Aina A, Ito R, Takeda S, Kawai T, Atsumi Y, Itoh H, and Hasegawa H (2011).** Plasma 25-Hydroxyvitamin D Is Independently Associated with Hemoglobin Concentration in Male Subjects with Type 2 Diabetes Mellitus. *International Journal of Endocrinology*;2011: 362981
- 65.**Mollsten AV, Dahlquist GG, Stattin EL, and Rudberg S (2001).** Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. *Diabetes Care*; 24:805-810.
- 66.**Murussi M, Baglio P, Gross JL, and Silveiro SP (2002).** Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. *Diabetes Care*; 25:1101-1103.
67. • **Ng T, Marx G, Littlewood T, and Macdougall I(2003).** Recombinant erythropoietin in clinical practice. *Postgrad Med J*; 79 (933):367-376.

-
68. **Ning S, Hartley C, Molineux G, and Knox SJ (2005).** Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected uncorrected anemia. *Cancer Res*; 65(1):284-290.
69. **Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, and Fioretto P (2000).** Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. *Diabetes*; 49(3):476-484 .
70. **National Kidney Foundation. NKF KDOQI Guidelines 2000:** Guidelines for Anemia of Chronic Kidney Disease: III Iron Support. www.kidney.org. Accessed 4/25/10.
71. **Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, Campagna SM, and Nuti R (2006).** Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. *Am Heart J*; 152(6):1099-1015 .
72. **Palazzuoli A, Silverberg DS, Iovine F, Calabro A, Campagna MS, Gallotta M, and Nuti R (2007).** Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. *Am Heart J*; 154(4):649-615.
73. • **Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DP, Placha G, Canani LH, Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS, Smiles A, Walker WH, Boright AP, Bull SB; DCCT/EDIC Research Group, Doria A, Rogus JJ, Rich SS, Warram JH, and Krolewski AS (2009).** Genome-wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes Mellitus. *Diabetes*; 58(6):1403-1410.
74. **Pocock S.** Group Sequential Methods in the Design and Analysis of Clinical Trials. *Biometrika* 1977;64:191-9
75. **Pocock S.** Interim Analysis for Randomized Clinical Trial: The Group Sequential Approach. *Biometrics* 1982;38:153-62

-
76. **Pouwer F, Kupper N, and Adriaanse MC (2010).** Does emotional stress cause type 2 diabetes mellitus? A review from the European Depression in Diabetes (EDID) Research Consortium. *Discovery Medicine*; 9 (45):112-8.
77. **Pratley RE and Weyer C (2001).** The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. *Diabetologia*; 44:929-945.
78. **Procrit [Package Insert].** Raritan, NJ. Centocor Ortho Biotech Products, L.P.; 2010
79. **Prentki M, Joly E, El Assaad W, and Roduit R (2002).** Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. *Diabetes*; 51:405-413.
80. **Provatopoulou ST and Ziroyiannis PN (2011).** Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. *Hippokratia*; 15 (2): 109-115.
81. **Parfrey P, Foler R, Wittreich B, et al.** Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease. *J Am Soc Nephrol* 2005;16:2180-89
82. **Reaven GM(1998).** The role of insulin resistance in human disease. *Diabetes*; 37:1595-1607.
83. **Reddy MK, Vasir JK, Hegde GV, Joshi SS, and Labhasetwar V (2007).** Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. *J Cardiovasc Pharmacol Ther*; 12(3):237-247 .
84. **Reinders ME, Rabelink TJ, and Briscoe DM (2006).** Angiogenesis and endothelial cell repair in renal disease and allograft rejection. *J Am Soc Nephrol*; 17(4):932-942.
85. **Remuzzi G, Ruggenti P, and Benigni A (1997).** Understanding the nature of renal disease progression. *Kidney Int*; 51:2-15.
86. **Ruggenti P and Remuzzi G (1998).** Nephropathy of type-2 diabetes mellitus. *J Am Soc Nephrol*; 9:2157-2169.

-
87. **Sarafian DA ,Shteinshnaider M, Irma Tzur I, Bar-Chaim A, Iskhakov E, Berman S, Efrati S, Modai D, Cohen N and Gorelik O (2010).** Anemia in diabetic patients at an internal medicine ward: Clinical correlates and prognostic significance *European Journal of Internal Medicine*;21(2):91-96.
88. **SchmidtRJ and Dalton CL (2007).** Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. *Osteopath Med Prim Care*; 1: 14.
89. **Scully MS, Ort TA, James IE, Bugelski PJ, Makropoulos DA, Deutsch HA, Pieterman EJ, van den Hoek AM, Havekes LM, DuBell WH, Wertheimer JD, and Picha KM (2011).** A Novel EPO Receptor Agonist Improves Glucose Tolerance via Glucose Uptake in Skeletal Muscle in a Mouse Model of Diabetes. *Experimental Diabetes Research*; 2011:910159.
90. **Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, and Lewis EJ (1999).** Captopril-induced reduction of serum levels of transforming growth factor-beta 1 correlates with long-term renoprotection in insulin-dependent diabetic patients. *Am J Kidney Dis*; 34:818-823.
91. **Shaw J and Chisholm D (2003).** Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. *MJA*; 179:379-383.
92. **ShlipakM (2010).** Diabetic nephropathy: preventing progression. *Clinical Evidence*; 7:606.
93. **Sigounas G, Sallah S, and Sigounas VY (2004).** Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. *Cancer Lett*; 214(2):171-179 .
94. **Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, and Iaina A (2003).** The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. *Nephrol Dial Transplant*; 118(1):141-146

-
95. **Silverberg DS, Wexler D, Iaina A, and Schwartz D (2006).** The interaction between heart failure and other heart diseases, renal failure, and anemia. *Semin Nephrol*; 26(4):296-306.
96. **Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, and Iaina A (2001).** The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. *J Am Coll Cardiol*; 37(7):1775-1780.
97. **Singh DK, Winocour P, Summerhayes B, Viljoen A, Sivakumar G, and Farrington K (2009).** Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria. *diabetes research and clinical practice*; 85:258 – 264.
98. **Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, and Parving HH (2002).** Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. *Diabetes*; 51:1157-1165.
99. **Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, and Holman RR (2000).** Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*; 321:405-412 .
100. **Singh A, Szczech L, Tang K.** Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. *N Engl J Med*. 2006;335:2085-98
101. **Shaw A.** Haemolysis in Chronic Renal Failure. *Br Med J* 1967;2:213-6
102. **Sikole A, Polenakovic M, Spirovska V, et al.** Analysis of Heart Morphology and Function Following-Erythropoietin Treatment of Anemic Dialysis Patients. *Artif Organs* 1993;17:977-984.

-
103. **Teehan G and BenzRL (2011).** An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost. *Anemia*; 201:623673.
 104. **Thomas R, Kanso A, John R and Sedor JR (2008).** Chronic Kidney Disease and Its Complications. *Prim Care Clin Office Pract*; 35(2):329-344.
 105. **Toma C, Letts DP, Tanabe M, Gorcsan J 3rd, and Counihan PJ (2007).** Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. *J Mol Cell Cardiol*; 43(2):130-136.
 106. **Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; and Finnish Diabetes Prevention Study Group (2001).** Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*; 344:1343-1350.
 107. **U.K. Prospective Diabetes Study Group (1998).** Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*; 352:837-853.
 108. **Unger E, Thompson A, Blank M, Temple R.** Erythropoiesis-Stimulating Agents – Time for a Reevaluation. *N Engl J Med*. 2010;362;3:189-192
 109. **Van Dam RM (2003).** The epidemiology of lifestyle and risk for type 2 diabetes. *Eur J Epidemiol*; 1115-1125.
 110. **Wild S, Roglic G, Green A, Sicree R, and King H (2004).** Global prevalence of diabetes. *Diabetes Care*; 27:1047-1053.
 111. **Will JC, Galuska DA, Vinicor F, and Calle E (1998).** Colorectal cancer: another complication of diabetes mellitus. *Am J Epidemiol*; 147:816-25.
 112. **Valderrabano F.** Improvement and Prevention of Left Ventricular Hypertrophy in Predialysis Patients. *J Am Soc Nephrol* 2000;11:78A [Abstract]
 113. **Wheeler D, Townend J, Landray M.** Cardiovascular Risk Factors in Predialysis Patients: Baseline Data from the Chronic Renal Impairment in Birmingham (CRIB) Study. *Kidney Int* 2003;63(84):5201-3

-
114. **Ware J, Sherbourne C.** The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual Framework and Item Selection. *Med Care* 1992;30:473-83
115. **Wizemann V, Kaufmann J, Kramer W.** Effect of Erythropoietin on Ischemia Tolerance in Anemic Hemodialysis Patients with Confirmed Coronary Artery Disease. *Nephron* 1992;62:161-5.
116. **Wolf G, Chen S, and Ziyadeh FN (2005).** From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. *Diabetes*; 54:1626-1634.
117. **Wu H, Ren B, Zhu J, Dong G, Xu B, Wang C, Zheng X, and Jing H (2006).** Pretreatment with recombinant human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. *Eur J Cardiothorac Surg*; 29(6):902-907.
118. **Yamagishi S, Matsui T, Ueda S, Nakamura K, and Imaizumi T (2007).** Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. *Cardiovasc Hematol Agents Med Chem*; 5:236- 240.
119. **Yun YS, Lee HC, Yoo NC, Song YD, Lim SK, Kim KR, Hahn JS, and Huh KB (1999).** Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. *Diabetes Res Clin Pract*; 46(3):223-229.
120. **Zanatta CM, Gerchman F, Burtet L, Nabinger G, Jacques-Silva MC, Canani LH, and Gross JL (2008).** Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract*; 80:299-304.
121. **Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, and Canani LH (2009).** Diabetic nephropathy. *Diabetology & Metabolic Syndrome*, 1:1:10.
122. **Zimmet P, Alberti KG, and Shaw J (2001).** Global and societal implication of the diabetes epidemic. *Nature*; 414:782-787.
123. **Zoppini G, Targher G, Chonchol MN, Negri C, Stoico V, Pichiri I, Lippi G, Muggeo M and Bonora E (2010).** Anemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients *Atherosclerosis*; 210(2):575-580.

-
124. **Astor BC, Muntner P, Levin A, et al.** Association of Kidney Function with Anemia: The Third National Health and Nutrition Examination Survey (1988-1994). *Arch Intern Med.* 2002. Jun 24;162(12):1401-8
 125. **Levin A, Singer J, Thompson C, et al.** Prevalent Left Ventricular Hypertrophy in the Predialysis Population: Identifying Opportunities for Intervention. *Am J Kidney Dis* 1996;27:347-54
 126. **Jurkovitz C, Abramson J, Vaccarino L, et al.** Association of High Serum Creatinine and Anemia Increases the Risk of Coronary Events: Results from the Prospective Community-based Atherosclerosis Risk in Communities (ARIC) Study. *J Am Soc Nephrol* 2003;14:2919- 25
 127. **Abramson J, Jurkovitz C, Vaccarino V, et al.** Chronic Kidney Disease, Anemia, and Incident Stroke in a Middle-Aged Community-Based Population: The ARIC Study. *Kidney Int* 2003;64:610-5
 128. **Epogen [Package Insert]. Thousand Oaks, CA. Amgen, Inc.; 2010**
 129. **Aranesp [Package Insert]. Thousand Oaks, CA. Amgen, Inc.; 2010**
 130. **Eschbach J, Egrie J, Downing M, et al.** Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin: Results of a Combined Phase I and II Clinical Trial. *N Engl J Med* 1987;316:73-8
 131. **Eschbach J, Abdulhadi M, Browne J, et al.** Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Trial. *Ann Intern Med* 1989;111:992-1000
 132. **Adamson J, Eschbach J, Finch C.** The Kidney and Erythropoiesis. *Am J Med* 1968;44:725-33.
 133. **Eschbach J, Adamson J.** Improvement in the Anemia of Chronic Renal Failure with Fluoxymesterone. *Ann Intern Med* 1973;78:527-32
 134. **Neff M, Goldberg J, Slifkin R, et al.** A Comparison of Androgens for Anemia in Patients on Hemodialysis. *N Engl J Med* 1981;304:87105

-
135. **Macdougall I, Lewis N, Saunders M, et al.** Long-Term Cardiorespiratory Effects of Amelioration of Renal Anaemia by Erythropoietin. *Lancet* 1990;335:489-93
136. **Canadian Erythropoietin Study Group:** Association Between Recombinant Human Erythropoietin and Quality of Life and Exercise Capacity of Patients Receiving Haemodialysis. *BMJ* 1990;300:573-578
137. **Cannella G, La Canna G, Sandrini M, et al.** Reversal of Left Ventricular Hypertrophy Following Recombinant Human Erythropoietin Treatment of Anaemic Dialysed Uraemic Patients. *Nephrol Dial transplant* 1991;6:31-7
138. **Pascual J, Teruel J, Moya J, et al.** Regression of Left Ventricular Hypertrophy After Partial Correction of Anemia with Erythropoietin in Patients on Hemodialysis: A Prospective Study. *Clin Nephrol* 1991;35:280-7
139. **Portoles J, Torralbo A, Martin P, et al.** Cardiovascular Effects of Recombinant Human Erythropoietin in Predialysis Patients. *Am J Kidney Dis* 1997;29:541-8
140. **McMahon L, Johns J, McKenzie A, et al.** Haemodynamic Changes and Physical Performance at Comparative Levels of Haemoglobin after Long-Term Treatment with Erythropoietin. *Nephrol Dial Transplant* 1992;7:1199-1206
141. **Besarab A, Bolton WK, Browne J, et al.** The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease who are Receiving Hemodialysis and Epoetin. *N Engl J Med.* 1998;339:584-90
142. **Drueke T, Locatelli F, Clyne N, et al.** Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. *N Engl J Med.* 2006;335:2071-84
143. **Food and Drug Administration (FDA) Alert. 11/16/06.**
<http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm124140.htm>
144. **Food and Drug Administration (FDA) Alert. 10/01/2008.**
[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109024.h tm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109024.htm)